BTK
Tyrosine-protein kinase BTK
As of the edition of 20 October 2026, BTK (tyrosine-protein kinase BTK, UniProt Q06187) has 40 drugs tested at it and 41 companies on the list, 12 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q06187
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 170
- Disease areas
- Immune system; Cancer; Blood and lymph; Skin and connective tissue; Heart and blood vessels; Lungs and airways; Nervous system; Bones, joints and muscles
- Registered trials of its drugs
- 1,133
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Active | 15 |
| Went quiet | 4 |
| Stopped | 9 |
| Status not established | 3 |
| Total | 40 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ibrutinib | Marketed | Phase 4 | Ends 2033 |
| Zanubrutinib | Marketed | Phase 4 | Ends 2037 |
| Acalabrutinib | Marketed | Phase 4 | Ends 2036 |
| Orelabrutinib | Active | Phase 4 | none listed |
| Pirtobrutinib | Marketed | Phase 4 | Ends 2036 |
| Ritlecitinib | Marketed | Phase 3 | Ends 2041 |
| Remibrutinib | Marketed | Phase 3 | Ends 2034 |
| Nemtabrutinib | Active | Phase 3 | none listed |
| Evobrutinib | Stopped | Phase 3 | none listed |
| Rilzabrutinib | Marketed | Phase 3 | Ends 2041 |
| Fenebrutinib | Active | Phase 3 | none listed |
| Tolebrutinib | Marketed | Phase 3 | none listed |
12 of 40 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 12 |
| Route B | 7 |
| Engaged | 19 |
| Undetermined | 3 |
| Total on the list | 41 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| Novartis | Route B |
| AstraZeneca | Route B |
The other 38 companies at BTK
In the product41 companies in all; 38 are not named here, and no score is.
See the 41 companies at BTK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.